Comparative Pharmacology
Head-to-head clinical analysis: TARACTAN versus THIORIDAZINE HYDROCHLORIDE INTENSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TARACTAN versus THIORIDAZINE HYDROCHLORIDE INTENSOL.
TARACTAN vs THIORIDAZINE HYDROCHLORIDE INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thioxanthene antipsychotic; blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic system; also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
Thioridazine is a typical antipsychotic of the phenothiazine class. It blocks dopamine D2 receptors in the brain, particularly in the mesolimbic pathway, and also exhibits antagonism at alpha-adrenergic, histaminergic H1, and muscarinic M1 receptors.
Oral: 25-50 mg three times daily, increased as needed to 400-600 mg/day. IM: 12.5-25 mg every 6-8 hours.
50 mg orally twice daily initially, titrated to 200-800 mg/day in divided doses. Maximum 800 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 20-40 hours (mean 30 hours). Steady-state reached in 5-7 days.
Terminal elimination half-life ranges from 21 to 30 hours (mean 24 h). In elderly or patients with hepatic impairment, half-life may be prolonged. Requires multiple days to reach steady state.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Metabolites eliminated renally (30%) and fecally (70%).
Primarily hepatic metabolism with <1% excreted unchanged in urine; metabolites eliminated in bile and feces. Approx. 30–40% of a dose appears in urine as metabolites (mostly sulfoxides and side-chain oxidized products) and 50–60% in feces.
Category C
Category A/B
Typical Antipsychotic
Typical Antipsychotic